Munakata Masanori, Nagasaki Akio, Nunokawa Tohru, Sakuma Toshiaki, Kato Hiroshi, Yoshinaga Kaoru, Toyota Takayoshi
Preventive Medical Center, Tohoku Rosai Hospital, Sendai, Japan.
Am J Hypertens. 2004 Nov;17(11 Pt 1):1050-5. doi: 10.1016/j.amjhyper.2004.06.028.
The aim of this study was to compare the effects of long-term antihypertensive treatment on brachial-ankle pulse wave velocity (PWV), a marker of systemic arterial stiffness, between angiotensin II receptor blocker valsartan and long-acting calcium channel blocker nifedipine coat-core.
Forty-one patients (54 +/- 3 years of age, 20 men and 21 women) with essential hypertension (155 +/- 3/95 +/- 3 mm Hg) were randomly allocated to the treatment with valsartan (80 mg once daily) or nifedipine coat-core (20 mg once daily). Brachial-ankle PWV and 24-h ambulatory blood pressures (BP) were measured before and 3 months after treatment.
Baseline data did not differ between the valsartan and nifedipine groups. The PWV also was similar between the groups (1669 +/- 65 v 1622 +/- 64 cm/sec). Three months of treatment similarly reduced resting systolic and diastolic BP (nifedipine, -18.4 +/- 4.2/-11.9 +/- 2.7 mm Hg; valsartan, - 17.4 +/- 3.3/-9.8 +/- 2.1 mm Hg, all P < .001). The PWV was significantly reduced compared with baseline values in the valsartan group (-195 +/- 42 cm/sec, P < 0.001) but not in the nifedipine group (-69 +/- 40 cm/sec, NS). The 24-h mean heart rate increased in the nifedipine group but remained unchanged in the valsartan group, although BP were similarly lowered for 24 h. A tachycardic response was associated with an increase or lesser reduction in PWV in a group treated with nifedipine (r = 0.584, P < .01).
These data suggest that long-term treatment with valsartan could reduce arterial stiffness better than nifedipine-coat core. The favorable vascular effect of valsartan was due in part to its nonhypotensive effect. The expected decrease in arterial stiffness may be offset by reflex sympathetic activation in some patients treated with nifedipine.
本研究旨在比较血管紧张素II受体阻滞剂缬沙坦与长效钙通道阻滞剂硝苯地平控释片对肱踝脉搏波速度(PWV,一种全身动脉僵硬度的标志物)的长期降压治疗效果。
41例原发性高血压患者(年龄54±3岁,男性20例,女性21例,血压155±3/95±3mmHg)被随机分配接受缬沙坦(80mg每日一次)或硝苯地平控释片(20mg每日一次)治疗。在治疗前和治疗3个月后测量肱踝PWV和24小时动态血压(BP)。
缬沙坦组和硝苯地平组的基线数据无差异。两组间的PWV也相似(1669±65对1622±64cm/秒)。治疗3个月同样降低了静息收缩压和舒张压(硝苯地平,-18.4±4.2/-11.9±2.7mmHg;缬沙坦,-17.4±3.3/-9.8±2.1mmHg,P均<0.001)。与基线值相比,缬沙坦组的PWV显著降低(-195±42cm/秒,P<0.001),而硝苯地平组未降低(-69±40cm/秒,无统计学意义)。硝苯地平组24小时平均心率增加,而缬沙坦组保持不变,尽管两组24小时血压均有相似程度的降低。在硝苯地平治疗组中,心动过速反应与PWV的增加或降低幅度较小有关(r=0.584,P<0.01)。
这些数据表明,长期使用缬沙坦治疗比硝苯地平控释片能更好地降低动脉僵硬度。缬沙坦有利的血管效应部分归因于其非降压作用。在一些接受硝苯地平治疗的患者中,预期的动脉僵硬度降低可能会被反射性交感神经激活所抵消。